Table 1.

Demographics.

	HC (n = 24)	PD (n = 27)	p value
Age at enrollment (years)	66.5 ± 8.1	69.3 ± 8.4	0.228
Gender (female/male)	16/8	8/19	0.008
Right-handed	100%	81%	0.085
OFF UPDRS Part III (motor) Score	4.1 ± 3.4	24.4 ± 11.2	< 0.001
OFF Total UPDRS Score	6.7 ± 4.5	40.1 ± 18.5	< 0.001
ON UPDRS Part III (motor) Score		16.6 ± 10.3 (n = 22)
ON Total UPDRS Score		28.1 ± 17.4 (n = 22)
Motor UPDRS (OFF–ON)		7.8 ± 6.9 (n = 22)
MOCA score	28.0 ± 1.7	26.1 ± 3.4	0.013
HAM-D	2.9 ± 3.2	6.3 ± 4.7	0.004
HAM-A	2.7 ± 3.0	4.7 ± 3.6	0.018
Right side more disease affected (MA)	–	56%
PIGD phenotype at visit	–	41%
Initial symptom (rest tremor/gait)	–	48%/15%
Freezing of gait reported at visit	–	37%
Age at onset (years)	–	60.1 ± 10.3
Disease duration (years)	–	9.2 ± 5.7
Hoehn & Yahr score	–	2.1 ± 0.8
Daily levodopa dose (mg/day)	–	667 ± 368 (n = 23)
levodopa per dose (mg/dose)	–	194 ± 84 (n = 23)
Duration on levodopa (years)	–	5.3 ± 3.2 (n = 23)
On dopamine agonist at visit	–	7%
On MAO-I at visit	–	33%
LEDD (l-dopa + agonist + MAO-I)	–	695 ± 393 (n = 24)

Significant p values are in bold.